Protective Actions of a Luminally Acting 5-HT Receptor Agonist in Mouse Models of Colitis

Overview

Journal Neurogastroenterol Motil

Specialties Gastroenterology
Neurology

Date 2023 Oct 13

PMID 37831752

Authors

Molly Hurd

Melody M Haag

Matthew J Kwasnik

Jill Wykosky

Brigitte Lavoie

Gary M Mawe

Affiliations

Soon will be listed here.

Abstract

Background: 5-hydroxytryptamine 4 receptors (5-HT Rs) are expressed in the colonic epithelium, and previous studies have demonstrated that luminal administration of agonists enhances motility, suppresses nociception, and is protective in models of inflammation. We investigated whether stimulation with a luminally acting 5-HT R agonist is comparable to previously tested absorbable compounds.

Methods: The dextran sodium sulfate (DSS), trinitrobenzene sulfonic acid (TNBS), and interleukin 10 knockout (IL-10KO) models of colitis were used to test the protective effects of the luminally acting 5-HT R agonist, 5HT4-LA1, in the absence and presence of a 5-HT R antagonist. The compounds were delivered by enema to mice either before (prevention) or after (recovery) the onset of active colitis. Outcome measure included disease activity index (DAI) and histological evaluation of colon tissue, and effects on wound healing and fecal water content were also assessed.

Key Results: Daily enema of 5HT4-LA1 attenuated the development of, and accelerated recovery from, active colitis. Enema administration of 5HT4-LA1 did not attenuate the development of colitis in 5-HT R knockout mice. Stimulation of 5-HT Rs with 5HT4-LA1 increased Caco-2 cell migration (accelerated wound healing). Daily administration of 5HT4-LA1 did not increase fecal water content in active colitis.

Conclusions And Inferences: Luminally restricted 5-HT R agonists are comparable to absorbable compounds in attenuating and accelerating recovery from active colitis. Luminally acting 5-HT R agonists may be useful as an adjuvant to current inflammatory bowel disease (IBD) treatments to enhance epithelial healing.

References

Li N, Ghia J, Wang H, McClemens J, Cote F, Suehiro Y . Serotonin activates dendritic cell function in the context of gut inflammation. Am J Pathol. 2011; 178(2):662-71. PMC: 3069907. DOI: 10.1016/j.ajpath.2010.10.028. View

Mawe G, Hoffman J . Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol. 2013; 10(8):473-86. PMC: 4048923. DOI: 10.1038/nrgastro.2013.105. View

Fukudo S, Nakamura M, Hamatani T, Kazumori K, Miwa H . Efficacy and Safety of 5-HT4 Receptor Agonist Minesapride for Irritable Bowel Syndrome with Constipation in a Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2020; 19(3):538-546.e8. DOI: 10.1016/j.cgh.2020.03.019. View

Fang X, Liu S, Wang X, Gao N, Hu H, Wang G . Neurogastroenterology of tegaserod (HTF 919) in the submucosal division of the guinea-pig and human enteric nervous system. Neurogastroenterol Motil. 2007; 20(1):80-93. DOI: 10.1111/j.1365-2982.2007.00983.x. View

Idzko M, Panther E, Stratz C, Muller T, Bayer H, Zissel G . The serotoninergic receptors of human dendritic cells: identification and coupling to cytokine release. J Immunol. 2004; 172(10):6011-9. DOI: 10.4049/jimmunol.172.10.6011. View

Kim J, Bridle B, Ghia J, Wang H, Syed S, Manocha M . Targeted inhibition of serotonin type 7 (5-HT7) receptor function modulates immune responses and reduces the severity of intestinal inflammation. J Immunol. 2013; 190(9):4795-804. DOI: 10.4049/jimmunol.1201887. View

Tougas G, Snape Jr W, Otten M, Earnest D, Pruitt R, Pecher E . Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2002; 16(10):1701-8. DOI: 10.1046/j.1365-2036.2002.01347.x. View

Bhattarai Y, Williams B, Battaglioli E, Whitaker W, Till L, Grover M . Gut Microbiota-Produced Tryptamine Activates an Epithelial G-Protein-Coupled Receptor to Increase Colonic Secretion. Cell Host Microbe. 2018; 23(6):775-785.e5. PMC: 6055526. DOI: 10.1016/j.chom.2018.05.004. View

Tack J, Camilleri M, Chang L, Chey W, Galligan J, Lacy B . Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012; 35(7):745-67. PMC: 3491670. DOI: 10.1111/j.1365-2036.2012.05011.x. View

10.

Hegde S, Eglen R . Peripheral 5-HT4 receptors. FASEB J. 1996; 10(12):1398-407. DOI: 10.1096/fasebj.10.12.8903510. View

11.

Makimoto N, Sakurai-Yamashita Y, Furuichi A, Kawakami S, Enjoji A, Kanematsu T . In vivo assessment of acceleration of motor activity associated with acetylcholine release via 5-hydroxytryptamine4 receptor in dog intestine. Jpn J Pharmacol. 2002; 90(1):28-35. DOI: 10.1254/jjp.90.28. View

12.

Matsuyoshi H, Kuniyasu H, Okumura M, Misawa H, Katsui R, Zhang G . A 5-HT(4)-receptor activation-induced neural plasticity enhances in vivo reconstructs of enteric nerve circuit insult. Neurogastroenterol Motil. 2010; 22(7):806-13, e226. DOI: 10.1111/j.1365-2982.2010.01474.x. View

13.

Hoffman J, Tyler K, MacEachern S, Balemba O, Johnson A, Brooks E . Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity. Gastroenterology. 2012; 142(4):844-854.e4. PMC: 3477545. DOI: 10.1053/j.gastro.2011.12.041. View

14.

Poole D, Xu B, Koh S, Hunne B, Coupar I, Irving H . Identification of neurons that express 5-hydroxytryptamine4 receptors in intestine. Cell Tissue Res. 2006; 325(3):413-22. DOI: 10.1007/s00441-006-0181-9. View

15.

Spohn S, Bianco F, Scott R, Keenan C, Linton A, ONeill C . Protective Actions of Epithelial 5-Hydroxytryptamine 4 Receptors in Normal and Inflamed Colon. Gastroenterology. 2016; 151(5):933-944.e3. PMC: 5159265. DOI: 10.1053/j.gastro.2016.07.032. View

16.

Liu M, Kuan Y, Wang J, Hen R, Gershon M . 5-HT4 receptor-mediated neuroprotection and neurogenesis in the enteric nervous system of adult mice. J Neurosci. 2009; 29(31):9683-99. PMC: 2749879. DOI: 10.1523/JNEUROSCI.1145-09.2009. View

17.

Prins N, Shankley N, Welsh N, Briejer M, Lefebvre R, Akkermans L . An improved in vitro bioassay for the study of 5-HT(4) receptors in the human isolated large intestinal circular muscle. Br J Pharmacol. 2000; 129(8):1601-8. PMC: 1572010. DOI: 10.1038/sj.bjp.0703254. View

18.

Han C, Geng Q, Qin J, Li Y, Yu H . Activation of 5-Hydroxytryptamine 4 Receptor Improves Colonic Barrier Function by Triggering Mucin 2 Production in a Mouse Model of Type 1 Diabetes. Am J Pathol. 2022; 192(6):876-886. DOI: 10.1016/j.ajpath.2022.03.002. View

19.

Quigley E, Wald A, Fidelholtz J, Boivin M, Pecher E, Earnest D . Safety and tolerability of tegaserod in patients with chronic constipation: pooled data from two phase III studies. Clin Gastroenterol Hepatol. 2006; 4(5):605-13. DOI: 10.1016/j.cgh.2006.02.017. View

20.

Liu M, Geddis M, Wen Y, Setlik W, Gershon M . Expression and function of 5-HT4 receptors in the mouse enteric nervous system. Am J Physiol Gastrointest Liver Physiol. 2005; 289(6):G1148-63. DOI: 10.1152/ajpgi.00245.2005. View